Parkinson&apos;s Disease and Cancer by D&apos et al.
STEROID ENZYMES AND CANCER
Parkinson’s Disease and Cancer
Insights for Pathogenesis from Epidemiology
Marco D’Amelio,a Paolo Ragonese,a Gabriella Sconzo,b
Paolo Aridon,a and Giovanni Savettieria
aDipartimento Universitario di Neuroscienze Cliniche, Universita´ degli Studi di Palermo,
Palermo, Italy
bDipartiomento di Biologia Cellulare e dello Sviluppo, Universita´ degli Studi di Palermo,
Palermo, Italy
Epidemiological evidence suggests a reduced incidence of many common types of can-
cers in individuals with Parkinson’s disease (PD). Parkinson’s disease and cancer are
two diseases that result from an excessive signaling by one of two forces driving cells
to opposite directions. PD results from the excessive death of dopaminergic neurons
in the substantia nigra pars compacta (SNc) in the brain, while uncontrolled growth is
the key property of cancer. Parkinson’s disease is a complex disorder, probably due in
most of the cases to the interaction of environment and genes. Many genes responsible
for familial forms of PD are supposed to have a supportive role in regulating or main-
taining the cell cycle, a fact that allows us to assume their interaction in tumorigenesis.
Understanding the nature of these processes may help researchers find new and more
efficacious therapeutic approaches for both diseases.
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Introduction
Parkinson’s disease (PD) is the second most
common neurodegenerative disorder, after
Alzheimer’s disease. PD is associated with a
selective loss of dopaminergic neurons in the
nigrostriatal pathway of the brain, and patho-
logically it is characterized by the presence of
Lewy bodies whose primary structural compo-
nent is alpha-synuclein. Clinical manifestations
include motor abnormalities (tremor, rigidity,
slowness, balance problems), autonomic distur-
bances, and nonmotor symptoms (depression
and cognitive impairment).
The cause of PD is still unknown. Only in a
minority of cases is PD determined by major
gene mutations, while in most cases, nongenetic
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factors probably interacting with susceptibility
genes play the most important role.
Many environmental risk factors for PD
have been proposed on the basis of presumed
pathogenetic mechanisms of the disease. The
first evidence suggesting that PD might be
the consequence of environmental toxin goes
back to 1983, when several people developed
a parkinsonian syndrome after intravenous in-
jection of drugs contaminated with 1-methyl-
4-phenyl-1,2,3,6-tetra hydropyridine (MPTP).
MPTP was successively demonstrated to selec-
tively damage dopaminergic cells in the sub-
stantia nigra and therefore came the hypothe-
sis that exposure to environmental toxins was
possibly one of the causes of PD.1
Cigarette smoking and coffee consumption
are among the most studied risk factors for
PD. Consistent results across epidemiological
studies have been obtained showing a reduced
risk of PD among cigarette smokers and cof-
fee drinkers.2 PD risk is increased in men
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compared to women, and a protective role
of estrogens has been hypothesized.3–5 So far,
however, literature investigating this topic is not
yet definitive. Other factors have been investi-
gated (antioxidants, fat and fatty acids, dietary
iron) but results of the studies have been not yet
convincing.6
In recent years, the discovery of several
causative monogenetic mutations determined
an increase in the interest of the scientific com-
munity in PD. These mutations, however, ex-
plain only a small proportion of all PD, while
approximately 90% of cases are still considered
sporadic. Therefore, the pathogenetic mech-
anisms underlying the selective dopaminergic
cell loss in PD are still not understood. Mi-
tochondrial dysfunction, oxidative stress, and
protein mishandling seem to play a central role
in PD pathogenesis,7 and these processes, in
sporadic PD, might be induced by nongenetic
factors, probably interacting with susceptibil-
ity genes. The need to search for nongenetic
causes is still striking in order to further un-
derstand the pathogenesis of PD and develop
effective therapeutic strategies.
In the last two decades it has increasingly
been suggested that PD patients are in some
way protected from cancer. Some epidemiolog-
ical evidence suggests in fact a low incidence of
many common types of cancers in individuals
with PD.
In this article, we will first describe epidemi-
ological studies supporting the inverse associa-
tion between cancer and PD, and then we will
focus on possible explanations for the inverse
association.
Cancer and Parkinson’s Disease
Epidemiological Studies
Evidence in favor of the inverse associa-
tion between PD and cancer goes back to mid
1900s, when it was pointed that “for reasons
as yet unclear, cancer is phenomenally rare in
paralysis agitans.”8 Later a significant reduced
risk of death for cancer among PD patients was
reported.9
Recently epidemiologists approached the
study of the association between cancer and
PD in two different ways. Cancer and PD are
chronic disorders with a long time interval be-
tween the onset of pathogenic alterations and
clinical manifestations. As the association be-
tween PD and cancer might have several ex-
planations, it is methodologically important to
define, in order to estimate a cause−effect rela-
tionship, if cancer happens before or after PD
onset. While in the case of onset of cancer be-
fore PD the best study design is a case-control
study, a cohort design is the best method to esti-
mate the incidence of cancer in previously diag-
nosed PD patients. Therefore, this review will
gather results of studies stratified by those who
looked at cancer occurrence before PD onset
(Table 1) and those who estimated cancer inci-
dence in PD patients (Table 2).
Cancer Preceding PD Onset
Only four studies looked at the frequency
of cancer preceding PD onset. The first study
was conducted in Rochester, Minnesota.10 This
was a population-based case-control study per-
formed using the medical records linkage sys-
tem of the Rochester Epidemiology Project.
One-hundred ninety-six PD incident cases dur-
ing the period 1976–1995 were matched by age
and gender to a general population control.
Overall frequency of cancer was lower in cases
(19.4%) than in controls (23.5%). The inverse
association was stronger in women and in indi-
viduals younger than 71 years of age. Though
none of the associations reached the statistical
significance, bladder and breast cancer were
less frequent among cases, while prostate can-
cer was more common among controls.
The second case-control study, chronologi-
cally, was based on prevalent PD cases.11 Start-
ing from a sample of 368 individuals complain-
ing of parkinsonian signs, the authors included
in the study a sample of 222 PD individu-
als. In fact, excluded from the original sample
were those individuals not satisfying PD criteria
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(110 patients), those with a Mini-Mental State
Examination (MMSE) score lower than 24 (25
patients), and 11 persons refusing to partici-
pate in the study. Cases were then matched
by age and gender to 222 PD free individ-
uals. The frequency of cancer preceding PD
onset was significantly lower among PD pa-
tients (6.8%) compared to controls (12.6%).
Also, this study found a decreased significant
risk of cancer only for women and, though
based on small numbers, in spite of an over-
all reduced risk of cancer in PD patients, breast
cancer was twice more common among cases
than in controls.
The third study observed an increased signif-
icant prevalence of malignant melanoma and
skin carcinoma prior to the first hospital con-
tact for PD,12 with an overall odds ratios of
1.4 (95% CI 1.0–2.0) and 1.3 (95% CI 1.1–
1.4), respectively. On the contrary, a reduced
prevalence of cancers at smoking-related sites
in patients before their first hospital contact
for Parkinson’s disease was observed. Findings
of this study supported previous observation of
an increased risk of melanoma prior to PD di-
agnosis observed by Elbaz et al. (OR 1.5; 95%
CI 0.3–9.0), weakening the hypothesis that skin
cancers might be caused by PD treatment. For
the authors the finding of a decreased preva-
lence of smoking-related cancers preceding
Parkinson’s disease was consistent with the well-
known higher risk of Parkinson’s disease among
nonsmokers.
Finally, the most recent study13 used data
from the Physician’s Health Study (PHS), en-
rolling 22,071 male physicians. The authors
identified 487 PD incident cases and matched
them to 487 controls. They then evaluated a
history of cancer prior to the index date that
was confirmed by medical record review. Also
this study observed a decrease, though not sig-
nificant, frequency of cancer of any type pre-
ceding the diagnosis of PD.
Cancer after PD Onset
Studies estimating cancer incidence in PD
patients are more abundant. The first study
used data from two separate surveys and cal-
culated the expected incidence rates for malig-
nancies in a sample of 406 PD patients with
PD.14
Cancer incidence was about one-third that of
the general population. Relative risk of cancer
increased after the onset of PD and after the
treatment was started, but it was still half that
of the general population. Thyroid cancer in
females (3 cases) and melanomas (2 cases) were
significantly more common in PD patients than
expected.
Using three computerized registries in Den-
mark15 a cohort of 7046 patients with PD,
located from three computerized Danish reg-
istries, were matched to the Danish cancer reg-
istry and the Danish registry of deaths. Cancer
incidence in PD patients (observed number of
cases) was compared to the expected number of
cancer cases. A significantly lower risk of cancer
was observed for PD patients (relative risk [RR]
0.88). In particular, PD patients had a lower risk
of smoking-related cancer (lung and bladder),
while they showed a two-fold increased risk of
malignant melanoma.
A prognosis study of 246 PD patients16
identified in an epidemiological survey on the
number of patients treated for intractable neu-
rological diseases reported a lower, though not
significant, decreased risk of cancer in both gen-
ders. However, risk of breast cancer was 5.5
times higher in PD patients compared to the
general population.
A significant increased risk of breast cancer
was also observed in a Danish study,17 which
observed also a twofold increased risk for ma-
lignant melanomas and a slight increased inci-
dence of nonmelanocytic skin cancers. Overall,
smoking-related cancers were less common in
PD patients. Interestingly, as already reported
by other authors, risk for melanoma skin cancer
decreased gradually with increasing periods of
follow-up, making less likely a role of levodopa
treatment in melanoma development.
Incidence of cancer18 was ascertained in an
historical cohort of PD patients. Risk of can-
cer was higher among PD patients than in
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the general population (RR 1.6; 95% CI 1.2–
2.4), but most cancer risk was attributable to
melanoma skin cancer (RR 1.8; 95% CI 1.1–
1.9). The estimate of the effect of the cumulative
dose of levodopa was specifically calculated
and no evidence for a dose-effect relation was
observed.
In the last study19 487 incident cases of
PD without cancer preceding PD onset were
identified and matched to PD-free individu-
als. Consistent with previous studies individ-
uals with PD had a lower cancer risk. PD
patients had in particular less lung (RR 0.3),
colorectal (RR 0.54), and bladder (RR 0.68)
malignancies. Among the studies described,
this was the one with the highest significant
risk for melanoma skin cancer (RR 6.15). How-
ever, smoking status significantly modified the
relationship between PD and smoking-related
cancers, suggesting a gene−environment inter-
action. PD patients who smoked were in fact at
a reduced risk for smoking-related cancers (RR
0.33), whereas nonsmoker PD patients were at
increased risk (RR 1.8).
Discussion
Case-control studies and large prospective
studies reported a suggestive decreased fre-
quency of smoking and nonsmoking related
cancers among patients with PD. Though most
cancers appear to be less common, a few can-
cer types, including melanomas, thyroid, and
breast cancer, have been reported to occur with
increased rates in PD patients.
Ultraviolet radiation (UVR) exposure and
individual phenotype are well-known major eti-
ologic risk factors for cutaneous melanoma.20
PD patients might have higher risk of
melanoma skin cancer because of high solar
exposure due to other risk factors for PD (i.e.,
rural living, farming). The association between
Parkinson’s disease and melanoma could be
explained by the association between farm-
ing and/or rural living, both conditions gen-
erally associated with higher solar exposure,
and PD. However, it seems unlikely that PD
patients are individuals who significantly spend
more time than the general population in the
sunlight.
Other possible explanations consider the
common embryonic origin of melanocytes and
neurons. Levodopa is a substrate for the syn-
thesis of melanin, and though according to
some authors increased rate of melanoma in
PD patients is unrelated to levodopa treat-
ment,21 one of the most recent hypotheses
linked these malignancies to the levodopa
in genetic-susceptible individuals,22 suggesting
again a gene−environment interaction.
Breast cancer is also more frequent in PD
patients than in the general population. As-
certainment bias must be considered, as indi-
viduals with PD are more likely to seek medi-
cal care and receive a diagnostic investigation
than individuals without PD. This statement
is also supported by the contrasting result of
an inverse association between breast cancer
and PD when tumors are diagnosed before PD
onset.10
While we could have doubts about the pre-
disposition for PD patients to develop some
cancers, we are also more prone to believe to
the inverse association between malignancies
and PD.
The risk that a tumor is underdiagnosed in
PD patients is very low. On the contrary, as it
has already been suggested, patients with PD
are more likely to see a medical doctor and
as a result they would have higher risk to be
diagnosed with a second disease.
PD is due to neurodegeneration of dopamin-
ergic neurons of the substantia nigra, and it
is just the process leading to cell death that
might explain the relationship between PD and
cancer.
The discovery of gene mutations associated
with familial parkinsonian disorders and under-
standing their role in cell survival and cell death
may unravel the relationship between these two
disorders.
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TABLE 3. Familial Forms of PD
Type Loci Gene Inheritance
PARK1 4q21-23 α-synuclein AD
PARK2 6q25.20-27 parkin AR
PARK3 2p13 unknown AD
PARK4 4q21-23 α-synuclein AD
PARK5 4p14 UCH-L1 AD
PARK6 1p35-36 PINK1 AR
PARK7 1p36 DJ-1 AR
PARK8 12p11.2-q13.1 LRRK2 AD
PARK9 1p36 ATP13A2 AR
PARK10 1p32 unknown SP
PARK11 2q36-37 unknown AD
PARK12 Xq21-25 unknown SP
PARK13 2p13 Omi/HtrA2 AD?
AD = autosomal dominant; AR = autosomal
recessive; S = sporadic
Familial Forms of
Parkinson’s Disease
Thirteen chromosome loci (Table 3) linked
to familial forms of PD have been until now
identified. As PARK1 and PARK4 represent
the same locus, the number of the familial forms
is 12.
PARK1- and PARK4-linked PD is an auto-
somal dominant one, caused by mutations of
the alpha-synuclein gene (SNCA); PARK1 is
caused by missense mutations and PARK4 by
multiplications of SNCA.
Alpha-synuclein was found to be widely
expressed both in a variety of brain tu-
mors23,24 such as medulloblastoma, neuroblas-
toma, pineoblastoma, and ganglioma, as well
as in peripheral cancers, including ovarian and
breast cancers.25 Recently, alpha-synuclein-
overexpressing cells transfected to human os-
teosarcoma MG63 cell line26 exhibited distinct
features of differentiated osteoblastic pheno-
type. In alpha-synuclein-overexpressing cells,
proteasome and kinase C activity were signif-
icantly decreased, while activity of lysosome
was upregulated. Taken together these results
suggest that the stimulatory effect of alpha-
synuclein on tumor differentiation may be
attributed to downregulation of proteasome,
which is further modulated by alterations of
various factors, such as protein kinase C sig-
naling pathway and a autophagy−lysosomal
degradation system. It has been hypothesized
that PD-related molecules might converge to
regulate the activity of ubiquitin proteasome
system (UPS) in tumor differentiation.
Parkin (PARK2) is the most common cause
of inherited PD,27–29 accounting for up to 49%
of familial recessive early-onset PD cases. The
parkin gene is characterized by a large 1.4-
Mb genomic structure covering more than 40%
of the 6q25-q27 chromosomal region,30 which
frequently undergoes deletions in a wide spec-
trum of human neoplasms, such as hepatocel-
lular carcinoma,31 ovarian and breast cancer,32
and hematological neoplasm.33
The deregulation of the parkin gene, ob-
served in various human cancers, suggest that
the parkin gene is important in tumorigenesis.
In particular, parkin gene may play an im-
portant role in the development of mammary
and ovarian tumors.34 In this study DNA
from 20 malignant breast tumors, 20 ovar-
ian tumors, and corresponding nontumor tis-
sues were genotyped. The analysis revealed
deletions at the 6q25-q27 locus in 55% of
cases analyzed. Subsequently, analysis of parkin
gene expression in a variety of human can-
cers, including malignant ovarian and breast
tumors, revealed the reduction of lack of tran-
script in approximately 70% of the samples
examined.
The authors concluded suggesting that
parkin is a strong candidate tumor suppres-
sor gene (TSG), located at human chromo-
some 6q25-q27, and that its reduced expression
and inactivation by hemizygous or homozygous
deletion may play an important role in ovar-
ian and breast carcinogenesis and other human
tumors.
Later, the histological spectrum of tumors
in which the candidate TSG parkin is geneti-
cally altered was expanded also to non-small-
cell lung cancer.35
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Recently,36 a parkin−/− mouse lacking
exon 3 of the parkin gene showed hepato-
cyte proliferation and developed macroscopic
hepatic tumors with the characteristics of hep-
atocellular carcinoma. Microarray analyses re-
vealed that parkin deficiency caused the al-
teration of gene expression profiles in the
liver. Among them, endogenous follistatin is
commonly upregulated in both nontumorous
and tumorous liver tissues of parkin-deficient
mice. Parkin deficiency resulted in suppres-
sion of caspase activation and made hepa-
tocytes resistant to apoptosis in a follistatin-
dependent manner. These results suggested
that parkin deficiency caused enhanced hep-
atocyte proliferation and resistance to apop-
tosis, resulting in hepatic tumor development.
The finding that parkin-deficient mice are sus-
ceptible to hepatocarcinogenesis provided the
evidence that parkin is indeed a tumor suppres-
sor gene.
Although this finding suggests that parkin is
a TSG, it is not clear whether mutations in the
gene, found in patients with PARK2, results in
increased risk of cancer.
PARK5-linked PD is an autosomal dom-
inant PD. The disease gene was reported
as ubiquitin carboxyl-terminal hydrolase-L1
(UCH-L1).37 UCH-L1 is an enzyme that
cleaves carboxy-terminal peptide bond of
polyubiquitine chains. Thus, UCH-L1 is an
ubiquitin-recycling enzyme. UCH-L1 is a
neuron-specific enzyme and is one of the
most abundant proteins in the brain, but also
presents in neuroendocrine cells in the lung.
Human lung cancers, in fact, frequently
overexpress the ubiquitin carboxyterminal hy-
drolase UCHL1.38 Aberrant DNA methylation
is associated with many types of human can-
cers. A microarray analysis for genes whose
expression was induced by treatment of hu-
man colon cancer cells with a demethylating
agent39 showed an upregulation and overex-
pression of seven known genes. Among these
was the UCHL1 gene. UCHL1 silencing was
observed in 11 of 12 human colorectal can-
cer cell lines, and its methylation was detected
in 8 of 17 primary colorectal cancers. Further,
UCHL1 silencing was observed in 6 of 13 ovar-
ian cancer cell lines, and its methylation was
detected in 1 of 17 primary ovarian cancers.
These results showed that UCHL1 is inacti-
vated in human colorectal and ovarian can-
cers by its promoter methylation, suggesting
that disturbance of cellular ubiquitin levels is
present. Regarding the ubiquitin−proteasome
system, to which UCHL1 belongs, its impor-
tant roles in various cellular processes, such as
cell cycle, apoptosis, and intracellular signaling,
and its disturbances in cancer development are
well recognized.40,41
PARK7-linked PD is another young onset
PD. The disease gene was identified as DJ-1.42
The size of DJ-1 is 24 kb with 8 exons encod-
ing a protein consisting of 189 amino acids.
PARK7-linked PD is very rare, and the func-
tion of DJ-1 protein is not well known. DJ-1 is
a cytoplasmic protein that can translocate into
the mitochondria. It has a strong antioxidative
property.43 Downregulation of endogenous DJ-
1 protein of neuronal cell line was reported to
enhance the cell death induced by oxidative
stress.44 DJ-1 protein expression is increased
upon oxidative stress induced by paraquat.45
As nigral neurons are exposed to high oxida-
tive stress owing to the presence of dopamine,
DJ-1 may be act as a strong antioxidative
protein.
DJ-1 has been identified as a novel suppres-
sor of PTEN (phosphatase and tensin homolog,
a a human gene that acts as a tumor suppres-
sor gene.46,47 It seems to play a role in human
tumorigenesis and also to be a useful prognos-
tic marker for cancer. Breast cancer patients
have elevated levels of serum DJ-1 and circu-
lating anti-DJ-1 autoantibodies.48 Moreover it
is increased in primary non-small-cell lung car-
cinoma samples.49
Mutations in the PTEN-induced putative ki-
nase (PINK1, of the PARK6 locus) have been
recently identified in individuals with PD.50,51
PARK6-linked PD is another form of young
onset autosomal recessive PD. PINK1 has eight
exons and cDNA spans 1.8 kb. It encodes a
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protein with 581 amino acids. The protein is
ubiquitously expressed including brain and sys-
temic organs. Interestingly, it is a mitochondrial
protein located in the matrix and the intermem-
brane space.
PINK1 have been shown to regulate cell
death and/or the cell cycle, and several lines
of evidence imply that malfunction of a shared
biochemical pathway may lead to PD or cancer.
PINK1 in fact encodes a kinase that is down-
regulated in the absence of PTEN.52
Tough premature—as the most common
domain encoded by cancer genes is the
protein-kinase domain53—mutations in the
leucine-rich-repeat kinase 2 gene (LRRK2 of
the PARK8 locus) recently identified in indi-
viduals with PD could also influence cell-cycle
control.54 PARK8-linked PD is now believed to
be the most common form of autosomal dom-
inant familial PD. Function of LRRK2 is not
well-known, but alterations of LRRK2 protein-
reducing kinase activity corresponded to a re-
duced neuronal toxicity.55
Conclusions
In this review we summarized results of
epidemiological studies showing an overall re-
duced risk of cancer in patients with Parkin-
son’s disease compared to that of general pop-
ulation. Whereas the risk of most cancers is
reduced in PD patients, melanomas and breast
cancers seem to occur more frequently in the
PD population compared to controls. Cancer
risk reduction cannot be attributed solely to the
well-known reduced smoking habit of PD pa-
tients, as not only do smoking-related cancers,
but also nonsmoking-related cancers appear to
be less frequent in PD patients.
The explanation of this peculiar finding
might be related to the involvement of common
genes in both the diseases. PD-linked genes in-
fluencing cell-cycle control and predisposing in-
dividuals either to develop Parkinson’s disease
or a specific cancer provide in fact a biological
basis for results of epidemiological studies.
Health or disease states are determined for
all individuals by interactions between genes
and environment. How the environment mod-
ifies gene expression and how this can incline an
individual to develop a disease needs to be ex-
plored in a productive way, one that considers
exposure to known risk factors in genetically
predisposed individuals. Future epidemiologi-
cal studies will benefit from study designs that
verify not only if specific types of cancers are
more closely associated with PD, but in partic-
ular if they are associated with specific familial
forms of PD. This will provide insights into the
function of genes associated with Parkinson’s
disease, characterize biological pathways, and
be important for the development of therapies
directed to the cure of neurodegenerative dis-
eases and malignancies.
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